Results 251 to 260 of about 50,472 (297)
Some of the next articles are maybe not open access.
Re: Stereotactic Body Radiotherapy for Oligometastatic Disease
Clinical Oncology, 2015Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer with comparable local control rates to surgical resection. Owing to the conformity of treatment dose delivery and with appropriate fractionation considerations, minimal side-effects to surrounding normal tissues are observed in most patients.
G.G. Hanna, D. Landau
openaire +5 more sources
Ultra-hypofractionated Radiotherapy (Stereotactic Body Radiotherapy)
2021Over the past two decades, interest in hypofractionated radiotherapy for prostate cancer has intensified. Research has indicated that prostate cancer cells may have a lower alpha/beta ratio than once supposed, and hypofractionation could widen the therapeutic window.
Michael C. Repka +7 more
openaire +1 more source
Stereotactic Body Radiotherapy/Stereotactic Ablative Body Radiotherapy for Lung Cancer
2013Technological advances in radiation oncology have led to clinical implementation of novel treatment modality. Stereotactic body radiotherapy (SBRT)/stereotactic ablative body radiotherapy (SABR) is an emerging treatment paradigm as a result of image-guidance technology and more sophisticated computational treatment planning system.
Hua Ren, Shanda Blackmon, Bin S. Teh
openaire +1 more source
Stereotactic Body Radiotherapy for Liver Metastases
Seminars in Radiation Oncology, 2017Many cancers can spread to the liver, often as the sole site of metastatic disease. For properly selected patients with limited hepatic disease and good performance status, an aggressive strategy involving radical local therapy to the site(s) of metastasis offers a chance for extended disease-free survivorship.
Karyn A, Goodman, Brian D, Kavanagh
openaire +2 more sources
Emerging Applications of Stereotactic Body Radiotherapy
Future Oncology, 2014Stereotactic body radiotherapy (SBRT) has been used extensively in patients with lung, liver and spinal tumors, and the treatment outcomes are very favorable. For certain conditions such as medically inoperable stage I non-small-cell lung cancer, liver and lung oligometastases, primary liver cancer and spinal metastases, SBRT is regarded as one of the ...
Simon S, Lo +11 more
openaire +2 more sources
Stereotactic Body Radiotherapy for Liver Metastases
Clinical Oncology, 2015The role for local ablative therapies in the management paradigm of oligometastatic liver disease is increasing. The evidence base supporting the use of stereotactic body radiotherapy for liver metastases has expanded rapidly over the past decade, showing high rates of local control with low associated toxicity. This review summarises the evidence base
Aitken, K, Hawkins, M
openaire +3 more sources
Stereotactic body radiotherapy for unresectable cholangiocarcinoma
Radiotherapy and Oncology, 2010To report outcomes of a single institution study of stereotactic body radiotherapy (SBRT) for unresectable cholangiocarcinoma. The dose-volume dependency of the observed gastrointestinal toxicity is explored.Twenty-seven patients with unresectable cholangiocarcinoma (n=26 Klatskin tumours and one intrahepatic cholangiocarcinoma (IHCC)) were treated by ...
Kopek, Neil +3 more
openaire +3 more sources
Stereotactic Body Radiotherapy for Prostate Cancer
Clinical Oncology, 2015The use of stereotactic body radiotherapy (SBRT) for localised prostate cancer is now supported by a substantial body of non-randomised data, with medium-term outcomes consistent with current standard radiotherapy. The ability to deliver profoundly hypofractionated treatment, combined with the relatively low α/β ratio of prostate cancer, may result in ...
D R, Henderson, A C, Tree, N J, van As
openaire +2 more sources
Spinal Stereotactic Body Radiotherapy
2018Patients treated for advanced cancer are often diagnosed with spinal metastases. During the course of their illness, most will be offered radiation treatment with external beam radiotherapy (EBRT). With improvement in systemic therapies and increasing cancer survivorship, local control and long-term pain control become significant therapeutic goals to ...
Annie Carbonneau +2 more
openaire +1 more source
Stereotactic Body Radiotherapy for Hepatocellular Carcinoma
The Cancer Journal, 2016Hepatocellular carcinoma (HCC) is a leading cause of cancer death. Experience with radiotherapy for HCC is increasing. Stereotactic body radiotherapy allows the delivery of tumoricidal doses in 3 to 6 treatments to focal HCC with low rates of toxicity and excellent local control. Stereotactic body radiotherapy can be used to control disease in patients
Andrew J, McPartlin, Laura A, Dawson
openaire +2 more sources